Saturday 17 October 2026
Export NEO’s income statement to Excel — free account
NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
16.65
0.60
−3.48%
Follow NEO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.40 | 2.07 | 1.28 | 2.47 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
111.59 | 1,121.72 | (117.78) | 94.76 | |
P/B ratio |
1.18 | 1.80 | 1.16 | 2.41 | |
Price to Tangible BV |
50.11 | 58.64 | 37.05 | 0.00 | |
EV/Sales |
1.93 | 2.60 | 1.82 | 3.03 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
100.08 | 361.35 | 60.47 | 105.45 | |
EV/FCF |
(80.35) | (95.87) | (448.59) | (439.62) | |
Quick Ratio |
3.26 | 3.61 | 3.71 | 3.03 | |
Current Ratio |
3.91 | 4.26 | 4.42 | 3.60 | |
Net Debt/EBITDA |
(17.39) | 54.18 | (107.27) | 32.27 | |
Debt/Assets |
24.84% | 25.14% | 25.42% | 27.97% | |
Debt/Equity |
0.41 | 0.41 | 0.41 | 0.48 | |
Asset Turnover |
0.47 | 0.49 | 0.51 | 0.56 | |
Operating CF/Net income |
(0.33) | (0.14) | 0.48 | 8.92 | |
Capex/Depreciation |
(0.49) | (0.35) | (0.30) | (0.48) | |
Interest Coverage |
(44.80) | (22.39) | (30.50) | (12.51) | |
Research and Development Expense of Revenue |
4.63% | 4.83% | 5.11% | 5.34% | |
Selling, General and Administrative Expense of Revenue |
48.82% | 45.72% | 47.98% | 45.07% | |
Intangible Assets out of Total Assets |
0.60 | 0.60 | 0.60 | 0.59 | |
Share Based Compensation of Revenue |
5.49% | 4.23% | 5.16% | 4.07% | |
Graham Net Nets |
(0.16) | (0.10) | (0.15) | (0.10) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.40%) | (7.14%) | (10.38%) | (2.74%) | |
Free Cash Flow Yield |
(1.72%) | (1.31%) | (0.32%) | (0.28%) | |
Revenue per Share |
1.46 | 1.48 | 1.45 | 1.56 | |
Operating CF per Share |
0.07 | 0.01 | (0.06) | 0.15 | |
Capex per Share |
(0.06) | (0.05) | (0.04) | (0.06) | |
Free Cash Flow per Share |
0.00 | (0.03) | (0.10) | 0.09 | |
Cash per Share |
1.28 | 1.25 | 1.13 | 1.12 | |
Shareholders Equity per Share |
6.53 | 6.53 | 6.42 | 6.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.53 | 6.53 | 6.42 | 6.06 | |
Free Cash Flow |
0.57 | (4.46) | (13.14) | 11.74 | |
Working Capital |
284.60 | 287.99 | 289.09 | 275.60 | |
Capital Expenditures |
(8.31) | (5.80) | (5.00) | (8.22) | |
Net Current Asset Value |
(154.02) | (146.98) | (144.09) | (185.03) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
153.36 | 154.89 | 159.32 | 164.27 | |
Average Payables |
19.56 | 22.35 | 21.05 | 24.22 | |
Average Inventory |
26.46 | 27.66 | 29.80 | 30.65 | |
Average Assets |
1,507.95 | 1,498.93 | 1,473.98 | 1,373.10 | |
Average Common Equity |
873.25 | 869.45 | 858.51 | 819.89 |
Columns are period end dates